This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Clinicaltrials.gov identifier

    NCT03922997

  • Recruitment Status

    Active, not recruiting

  • First Posted

    April 22, 2019

  • Last update posted

    April 1, 2021

Study Description

Brief summary:

This is a phase III, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in patients with Stage IIIb or Stage IV non-small cell lung cancer (NSCLC) who have progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy or after anti-PD-1 as monotherapy).

  • Condition or Disease:Non-small Cell Lung Cancer
  • Intervention/Treatment: Drug: Atezolizumab
  • Phase: Phase 3

Detailed Description

N/A

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: An Open-Label, Singe Arm, Multicenter Study to Investigate the Safety and Efficacy of Atezolizumab (Tecentriq) in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: August 2022
  • Estimated Study Completion Date: August 2022

Arms and interventions

Arm Intervention/treatment
Experimental: Atezolizumab
Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
Drug: Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.

Outcome Measures

  • Primary Outcome Measures: 1. Serious Adverse Event Incidence Rates [ Time Frame: Baseline up to approximately 3 years ]
    The incidence of serious adverse events (SAEs) related to atezolizumab.
  • Secondary Outcome Measures: 1. Overall Survival (OS) Rate [ Time Frame: Baseline to 2 years ]
    Overall survival (OS) rate at 2 years, defined as the proportion of patients remaining alive 2 years after initiation of study treatment
  • 2. OS [ Time Frame: Baseline up to approximately 3 years ]
    Overall survival (OS), defined as the time from initiation of study treatment to death from any cause
  • 3. Progression-Free Survival (PFS) [ Time Frame: Baseline up to approximately 3 years ]
    Progression-free survival (PFS), defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first.
  • 4. Objective Response Rate (ORR) [ Time Frame: Baseline up to approximately 3 years ]
    Objective response rate (ORR), defined as the percentage of patients who attain complete response (CR) or partial response (PR) according to RECIST v1.1 and also by disease status evaluated by the investigator according to modified RECIST
  • 5. Duration of Response (DOR) [ Time Frame: Baseline up to approximately 3 years ]
    Duration of response (DOR), defined as the time from initial response to disease progression or death among patients who have experienced a CR or PR (unconfirmed) during the study.
  • 6. EQ-5D-5L Index-Based and VAS scores [ Time Frame: Day 1 of first 3 cycles, then with tumor assessments every 6 weeks for 48 weeks from study treatment date; thereafter every 9 weeks until progressive disease or until treatment discontinuation (up to approximately 3 years) ]
    EQ-5D-5L, EuroQol 5-Dimension Questionnaire is a self-report health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. The EuroQol EQ-5D has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort and anxiety/depression, as well as a visual analog scale (VAS) that measures health state. Overall scores range from 0 to 1, with low scores representing a higher level of dysfunction.
  • 7. EORTC QLQ-LC13 score [ Time Frame: Day 1 of first 3 cycles, then with tumor assessments every 6 weeks for 48 weeks from study treatment date; thereafter every 9 weeks until progressive disease or until treatment discontinuation (up to approximately 3 years) ]
    EORTC QLQ-LC13, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Supplemental Lung Cancer Module will be used to assess self-reported outcomes. EORTC QLQ-LC13 includes 13 items that address key lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related adverse effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. The dysphagia scale is multi-item, while the rest are single-item scales.

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- Histologically or cytologically documented Stage IIIb or Stage IV NSCLC that has
progressed following standard systemic chemotherapy (including if given in combination
with anti-PD-1 therapy or after anti-PD-1 as monotherapy). Patients with a previously
detected EGFR mutation or ALK fusion oncogene will be excluded from this study.
Overall, patients should not have received more than two lines of systemic
chemotherapy. Patients who have discontinued first-line or second-line systemic
chemotherapy, targeted therapy, or anti-PD-1 therapy due to intolerance are also
eligible.

- The last dose of prior systemic anticancer therapy must have been administered ≥ 21
days prior to the first study treatment.

- The last dose of prior anti-PD-1 therapy must have been administered

- Measurable disease, as defined by Response Evaluation Criteria for Solid Tumors,
Version 1.1 (RECIST v1.1)

- Patients with asymptomatic CNS metastases (treated or untreated), as determined by CT
or MRI evaluation during screening and prior radiographic evaluation, are eligible

- ECOG performance status 0, 1, or 2

- Life expectancy ≥ 12 weeks

- Adequate hematologic and end-organ function

- For women of childbearing potential: agreement to remain abstinent or use
contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab - Patients must have recovered from all acute toxicities from previous therapy, excluding alopecia and toxicities related to prior anti-PD-1-therapy Exclusion Criteria: - Patients with EGFR mutation or ALK fusion oncogene - Symptomatic CNS metastases - Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 2 weeks prior to the first study treatment - Leptomeningeal disease - Uncontrolled pericardial effusion or ascites requiring recurrent drainage procedures - Pregnant or lactating, or intending to become pregnant during the study - Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, including significant liver disease - Significant cardiovascular disease - Significant renal disorder requiring dialysis or indication for renal transplant - Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to study treatment initiation - Major surgical procedure within 4 weeks prior to study treatment initiation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis - Prior allogeneic stem cell or solid organ transplantation

Contacts and Locations

Contacts

Locations

China
Peking Union Medical College Hospital
Beijing City

China
Sichuan Cancer Hospital
Chengdu City

China
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department
Hangzhou City

China
Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy
Harbin

China
Taizhou Hospital of Zhejiang Province
Linhai

China
Fudan University Shanghai Cancer Center; Medical Oncology
Shanghai

China
Cancer Hospital Affliated to Xinjiang Medical University
Urumqi City

Sponsors and Collaborators

Hoffmann-La Roche

Investigators

Study Director: Clinical Trials Hoffmann-La Roche

More Information

  • Responsible Party: Hoffmann-La Roche
  • ClinicalTrials.gov Identifier: NCT03922997 History of Changes
  • Other Study ID Numbers: ML40471
  • First Posted: April 22, 2019 Key Record Dates
  • Last Update Posted: April 1, 2021
  • Last Verified: March 2021
  • Individual Participant
    Data (IPD) Sharing
    Statement:

  • Plan to Share IPD: Yes
  • Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Lung Neoplasms Carcinoma, Non-Small-Cell Lung